Erytech's positive results get the ball rolling for AACR meeting

31 March 2017

French cancer-focused drug developer Erytech Pharma (Euronext Paris: ERYP) has announced positive topline results from its Phase IIb clinical study evaluating Graspa (eryaspase) in combination with chemotherapy for second-line metastatic pancreatic cancer.

The data has been presented just ahead of the American Association for Cancer Research (AACR) Annual Meeting, where Erytech will present further findings on its therapies, which it develops by encapsulating therapeutic drug substances inside red blood cells.

Erytech’s pancreatic cancer results on eryaspase, which is being explored in other cancers too and is already under review by the European Medicines Agency in the indication of acute lymphoblastic leukemia, showed significant improvement in progression-free survival (PFS) and overall survival (OS) in patients treated with the drug combined with chemotherapy compared to chemotherapy alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK